MoonLake Immunotherapeutics
MLTX
$13.35
$0.836.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -160.62% | -221.44% | -256.99% | -230.31% | -76.82% |
| Total Depreciation and Amortization | 129.21% | 168.19% | 241.34% | 527.14% | 10,365.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.44% | 40.49% | 400.67% | 512.38% | 257.31% |
| Change in Net Operating Assets | 353.45% | 120.75% | 86.38% | 39.16% | -390.22% |
| Cash from Operations | -130.79% | -158.28% | -187.01% | -172.54% | -91.43% |
| Capital Expenditure | 66.50% | 31.01% | 31.01% | -82.57% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 44.83% | 132.15% | -64.35% | -723.61% | 144.82% |
| Cash from Investing | 46.02% | 131.86% | -63.70% | -716.36% | 144.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.13% | -99.59% | -99.94% | -89.06% | -81.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 102.13% | 102.13% | 46.60% | -- |
| Cash from Financing | -7.32% | -7.48% | -86.16% | -89.30% | -82.37% |
| Foreign Exchange rate Adjustments | 723.35% | 1,320.26% | 78.47% | 269.72% | -55.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.35% | 77.29% | -145.77% | -165.77% | -79.24% |